全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2015 

非小细胞肺癌中线粒体DNA含量及A10398G位点多态性的预后价值 Prognostic Value of mtDNA Content and G10398A Polymorphism in NSCLC

Keywords: 非小细胞肺癌,线粒体DNA,mtDNA A10398G,预后

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:文献提示线粒体(mitochondrial,mt)DNA含量和10398位点突变情况可能为非小细胞肺癌(NSCLC)的预后提供新的分子靶标,本实验研究了NSCLC中这两项指标与预后的关系。方法:128例符合要求的NSCLC患者,RT-PCR检测mtDNA含量,RFLP检测10398位点突变情况。生存分析评估两指标的预后价值。结果:mtDNA含量低的患者较mtDNA含量高的患者生存期短(中位生存时间为27.9个月vs 34.1个月;χ2=3.742,P=0.053 0),但无统计学差异。单独分析G10398A多态性与预后也无显著差异。然而,mtDNA含量低且10398A的患者的总生存期显着短于mtDNA含量高且10398G的患者(中位生存期26.3个月vs 47.3个月;χ2=6.010;P=0.014 1)。Cox回归分析示,肿瘤分期及mtDNA加G10398A多态性是NSCLC两个独立的预后因素(χ2=6.235,P=0.013;χ2=18.515,P<0.000 5)。结论:NSCLC患者中,mtDNA含量低且10398A的患者的总生存期显着短于mtDNA含量高且10398G的患者;所以mtDNA含量和10398的基因型将会成为预测NSCLC的新的分子靶标

References

[1]  Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2]  Tretter L,Sipos I,Adam-Vizi V.Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson′s disease[J].Neurochem Res,2004,29(3):569-577.
[3]  Larsen NB,Rasmussen M,Rasmussen LJ.Nuclear and mitochondrial DNA repair:similar pathways?[J].Mitochondrion,2005,5(2):89-108.
[4]  Siegel R,Ward E,Brawley O,et al.Cancer statistics,2011:the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J].CA Cancer J Clin,2011,61(4):212-236.
[5]  Peng J,Yang LX,Zhao XY,et al.VCP gene variation predicts outcome of advanced non-small-cell lung cancer platinum-based chemotherapy[J].Tumour Biol,2013,34(2):953-961.
[6]  He L,Luo L,Proctor SJ,et al.Somatic mitochondrial DNA mutations in adult-onset leukaemia[J].Leukemia,2003,17(12):2 487-2 491.
[7]  Kulawiec M,Owens KM,Singh KK.mtDNA G10398A variant in African-American women with breast cancer provides resistance to apoptosis and promotes metastasis in mice[J].J Hum Genet,2009,54(11):647-654.
[8]  Yu M.Somatic mitochondrial DNA mutations in human cancers[J].Adv Clin Chem,2012,57:99-138.
[9]  Wang Y,Liu VW,Xue WC,et al.Association of decreased mitochondrial DNA content with ovarian cancer progression[J].Br J Cancer,2006,95(8):1 087-1 091.
[10]  Yu M,Wan Y,Zou Q.Reduced mitochondrial DNA copy number in Chinese patients with osteosarcoma[J].Transl Res,2013,161(3):165-171.
[11]  Chatterjee A,Dasgupta S,Sidransky D.Mitochondrial subversion in cancer[J].Cancer Prev Res(Phila),2011,4(5):638-654.
[12]  Pezzotti A,Kraft P,Hankinson SE,et al.The mitochondrial A10398Gpolymorphism,interaction with alcohol consumption,and breast cancer risk[J].PLoS One,2009,4(4):e5 356.
[13]  Johns DR.Seminars in medicine of theBeth Israel Hospital,Boston.Mitochondrial DNA and disease[J].N Engl J Med,1995,333(10):638-644.
[14]  Xing J,Chen M,Wood CG,et al.Mitochondrial DNA content:its genetic heritability and association with renal cell carcinoma[J].J Natl Cancer Inst,2008,100(15):1 104-1 112.
[15]  Hsu CW,Yin PH,Lee HC,et al.Mitochondrial DNA content as a potential marker to predict response to anthracycline in breast cancer patients[J].Breast J,2010,16(3):264-270.
[16]  Sanchez-Arago M,Chamorro M,Cuezva JM.Selection of cancer cells with repressed mitochondria triggers colon cancer progression[J].Carcinogenesis,2010,31(4):567-576.
[17]  Choi SJ,Kim SH,Kang HY,et al.Mutational hotspots in the mitochondrial genome of lung cancer[J].Biochem Biophys Res Commun,2011,407(1):23-27.
[18]  Kim MM,Clinger JD,Masayesva BG,et al.Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions[J].Clin Cancer Res,2004,10(24):8 512-8 515.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133